Status:
COMPLETED
Long-term Study in Chronic Kidney Disease (Extension From Study 14817)
Lead Sponsor:
Bayer
Collaborating Sponsors:
Shire
Conditions:
Hyperphosphatemia
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The objective of this study is to investigate the safety and the effect on reduction of serum phosphate of long-term administration of lanthanum carbonate (BAY77-1931) 750 to 2250 mg in patients with ...
Eligibility Criteria
Inclusion
- Patients who have completed the 8-week double-blind treatment period of Study 14817 and are judged to be eligible for the long-term extension study by the investigator (including those who plan to be on dialysis during the long-term extension study).
Exclusion
- Patients with any other conditions that the investigator defines as not appropriate to be enrolled in the study
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
123 Patients enrolled
Trial Details
Trial ID
NCT01187628
Start Date
September 1 2010
End Date
April 1 2013
Last Update
April 3 2015
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Anjo, Aichi-ken, Japan, 446-8602
2
Nagoya, Aichi-ken, Japan, 455-8530
3
Nagoya, Aichi-ken, Japan, 457-8510
4
Nagoya, Aichi-ken, Japan, 460-0001